Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its ...
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
MedPage Today on MSN6d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's DrugTreatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.
In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...
Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and ...
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback